IN8bio, Inc

Contributing Author

Recent Articles by IN8bio, Inc

Jun-03	IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies INAB GlobeNewswire
Jun-01	IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026 INAB -7.49% GlobeNewswire
May-14	IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma INAB GlobeNewswire
May-07	IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights INAB GlobeNewswire
May-06	IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences INAB GlobeNewswire
Apr-03	IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) INAB GlobeNewswire
Mar-12	IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026 INAB GlobeNewswire
Feb-24	IN8bio to Present at TD Cowen 46th Annual Health Care Conference INAB GlobeNewswire
Feb-09	IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer INAB GlobeNewswire
Feb-03	IN8bio to Present at Upcoming Investor and Scientific Conferences in February INAB GlobeNewswire
Jan-12	IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma INAB -7.23% GlobeNewswire
Dec-19	IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager INAB -12.32% GlobeNewswire
Nov-06	IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights INAB -6.63% INAB GlobeNewswire
Oct-29	IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site INAB GlobeNewswire
Oct-27	IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications INAB GlobeNewswire
Aug-07	IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights INAB +7.44% INAB GlobeNewswire
Jun-09	IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial INAB -26.14% GlobeNewswire
Jun-02	IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival INAB -9.78% GlobeNewswire
May-14	IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025 INAB -8.31% GlobeNewswire
May-12	IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products INAB GlobeNewswire
May-07	IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights INAB GlobeNewswire

IN8bio, Inc

Recent Articles by IN8bio, Inc

Upgrade your Finviz experience